Verrill Clare, Yilmaz Asli, Srigley John R, Amin Mahul B, Compérat Eva, Egevad Lars, Ulbright Thomas M, Tickoo Satish K, Berney Daniel M, Epstein Jonathan I
*Nuffield Department of Surgical Sciences, University of Oxford, Oxford ††Department of Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom †Department of Pathology and Laboratory Medicine, Calgary Laboratory Services and University of Calgary, Calgary, AB ‡Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada §Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Centre, Los Angeles, CA #Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN **Department of Pathology, Memorial Sloan Kettering Cancer Centre, New York, NY ‡‡Department of Pathology, John Hopkins Hospital, Baltimore, MD ∥Department of Pathology, Hopital Tenon, Assistance Publique - Hopitaux de Paris, Université Pierre et Marie Curie, Paris VI, Paris, France ¶Department of Pathology and Cytology, Karolinska Hospital, Stockholm, Sweden §§Members of the ISUP Testicular Tumor Panel: Brett Delahunt, Cristina Magi-Galluzzi, Ferran Algaba, Esther Oliva, Rodolfo Montironi, Robert H Young, Muhammad T Idrees, Sean R Williamson, Ming Zhou, Peter A Humphrey, Antonio Lopez-Beltran, and Joanna Perry-Keene.
Am J Surg Pathol. 2017 Jun;41(6):e22-e32. doi: 10.1097/PAS.0000000000000844.
The International Society of Urological Pathology held a conference devoted to issues in testicular and penile pathology in Boston in March 2015, which included a presentation and discussion led by the testis microscopic features working group. This conference focused on controversies related to staging and reporting of testicular tumors and was preceded by an online survey of the International Society of Urological Pathology members. The survey results were used to initiate discussions, but decisions were made by expert consensus rather than voting. A number of recommendations emerged from the conference, including that lymphovascular invasion (LVI) should always be reported and no distinction need be made between lymphatic or blood invasion. If LVI is equivocal, then it should be regarded as negative to avoid triggering unnecessary therapy. LVI in the spermatic cord is considered as category pT2, not pT3, unless future studies provide contrary evidence. At the time of gross dissection, a block should be taken just superior to the epididymis to define the base of the spermatic cord, and direct invasion of tumor in this block indicates a category of pT3. Pagetoid involvement of the rete testis epithelium must be distinguished from rete testis stromal invasion, with only the latter being prognostically useful. Percentages of different tumor elements in mixed germ cell tumors should be reported. Although consensus was reached on many issues, there are still areas of practice that need further evidence on which to base firm recommendations.
国际泌尿病理学会于2015年3月在波士顿召开了一次专门讨论睾丸和阴茎病理学问题的会议,其中包括由睾丸微观特征工作组主持的一场报告和讨论。本次会议聚焦于睾丸肿瘤分期和报告相关的争议问题,在此之前对国际泌尿病理学会成员进行了一次在线调查。调查结果用于启动讨论,但决策是通过专家共识而非投票做出的。会议提出了一些建议,包括应始终报告脉管侵犯(LVI),且无需区分淋巴侵犯或血行侵犯。如果LVI不明确,则应视为阴性以避免引发不必要的治疗。除非未来研究提供相反证据,精索内的LVI应归为pT2期,而非pT3期。在大体解剖时,应在附睾上方取一块组织以确定精索的基部,该组织块中肿瘤的直接侵犯表明为pT3期。睾丸网上皮的派杰样累及必须与睾丸网间质侵犯相区分,只有后者对预后有意义。应报告混合性生殖细胞肿瘤中不同肿瘤成分的百分比。尽管在许多问题上达成了共识,但仍有一些实践领域需要进一步的证据来做出可靠的建议。